Table 1 Baseline characteristics in case control study of cardiac events associated with PI therapy
From: Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Cases N = 21 | Controls N = 75 | |
|---|---|---|
Years of age, median (range) | 63 (46–86) | 59 (36–91) |
Male, n (%) | 11 (52) | 51 (68) |
Caucasian, n (%) | 13 (62) | 60 (80) |
Current or past smoker, n (%) | 11 (52) | 30 (40) |
Dyslipidemia, n (%) | 8 (38) | 18 (24) |
Type II diabetes, n (%) | 5 (24) | 9 (12) |
Kidney disease, n (%) | 3 (14) | 7 (9) |
10-Year ASCVD risk >20%, n (%) | 7 (37) | 8 (14) |
Prior cardiac event, n (%) | 16 (76) | 41 (55) |
Atrial fibrillation/flutter, n (%) | 3 (14) | 2 (3) |
CAD, n (%) | 3 (14) | 3 (4) |
Heart failure, n (%) | 4 (19) | 0 (0) |
Hypertension, n (%) | 15 (71) | 38 (51) |
Venous/arterial thromboembolism, n (%) | 3 (14) | 4 (5) |
Valvular disease, n (%) | 2 (10) | 1 (1) |
ACE inhibitor or ARB use, n (%) | 8 (38) | 24 (32) |
Antithrombotic use, n (%) | 11 (52) | 22 (29) |
Beta blocker use, n (%) | 11 (52) | 11 (15) |
Lipid lowering agent use, n (%) | 14 (67) | 17 (23) |
Loop diuretic use, n (%) | 4 (19) | 4 (5) |
Followed by cardio-oncologist | 7 (33) | 16 (21) |
Durie Salmon stage III, n (%) | 11 (52) | 47 (63) |
International Staging System III, n (%) | 5 (24) | 23 (31) |
Cytogenetic/FISH high risk, n (%) | 2 (10) | 8 (11) |
Received bortezomib only, n (%) | 7 (33) | 37 (49) |
Received carfilzomiba, n (%) | 14 (67) | 38 (51) |
Total days of PI therapy, median (range) | 407 (38–1032) | 250 (2–885) |